CUBRIVA 10mg/5ml Injection

CUBRIVA 10mg/5ml Injection contains the active ingredient Brivaracetam, which is an antiepileptic medication used to treat partial-onset seizures in adults. It belongs to the class of drugs known as selective synaptic vesicle protein 2A (SV2A) ligands, which modulate synaptic neurotransmission and reduce abnormal neuronal excitability. CUBRIVA Injection is formulated for intravenous administration and is indicated for the management of seizures when oral administration is not feasible or appropriate.

Key Ingredient:

Brivaracetam: Brivaracetam is a racetam derivative that selectively binds to synaptic vesicle protein 2A (SV2A), a protein involved in neurotransmitter release at synapses. By modulating synaptic transmission, Brivaracetam reduces neuronal excitability and helps prevent seizure activity. It is structurally related to levetiracetam, another antiepileptic medication, but exhibits higher affinity and potency for SV2A receptors.

Uses:

CUBRIVA 10mg/5ml Injection is indicated for the treatment of partial-onset seizures in adults with epilepsy. It is used as adjunctive therapy in combination with other antiepileptic drugs or as monotherapy when oral administration is not feasible or appropriate. CUBRIVA Injection provides rapid onset of action and can be administered in emergency situations to control acute seizures or status epilepticus.

Dosage:

The recommended dosage of CUBRIVA 10mg/5ml Injection is based on individual patient factors, including age, weight, renal function, and concomitant medications. It is administered intravenously over a period of 2 to 15 minutes, depending on the total dose and patient tolerance. The initial dose and subsequent titration should be guided by clinical response and tolerability. Dosage adjustments may be necessary in patients with renal impairment or hepatic dysfunction.

Precautions:

Before administering CUBRIVA Injection, assess the patient’s medical history, including any history of seizures, allergies, or renal impairment. Use caution in patients with a history of psychiatric disorders, as Brivaracetam may exacerbate mood changes or behavioral disturbances. Monitor patients closely for signs of hypersensitivity reactions, including rash, fever, or respiratory symptoms, and discontinue treatment if an allergic reaction occurs.

Side Effects:

Common side effects of CUBRIVA 10mg/5ml Injection may include:

• Dizziness
• Fatigue
• Somnolence
• Headache
• Nausea
• Irritability
• Abnormal behavior

These side effects are usually mild and transient. However, if you experience any severe or persistent side effects, discontinue use of CUBRIVA Injection and seek medical attention.

FAQs:

1. How does CUBRIVA Injection work? CUBRIVA Injection works by selectively binding to synaptic vesicle protein 2A (SV2A) receptors in the brain, thereby modulating synaptic neurotransmission and reducing abnormal neuronal excitability, which helps prevent seizure activity.
2. Can CUBRIVA Injection be used as monotherapy? CUBRIVA Injection can be used as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy. The choice of treatment should be individualized based on patient factors and clinical considerations.
3. Is CUBRIVA Injection safe for use in elderly patients? CUBRIVA Injection can be used in elderly patients with partial-onset seizures, but dosage adjustments may be necessary based on age, renal function, and other factors. Close monitoring for adverse effects is recommended in this population.
4. What should I do if I miss a dose of CUBRIVA Injection? If you miss a dose of CUBRIVA Injection, contact your healthcare provider or seek medical advice promptly. Do not double the dose to make up for a missed dose.
5. Can CUBRIVA Injection be administered at home? CUBRIVA Injection is typically administered in a healthcare setting by trained medical personnel. However, in some cases, it may be administered at home under the supervision of a healthcare provider. Follow your healthcare provider’s instructions for proper administration and monitoring.